Financial Performance - For the first three quarters of 2025, the company's unaudited consolidated revenue was HKD 9.45 billion, an increase of 10% compared to HKD 8.58 billion in the same period last year[7]. - The unaudited consolidated profit attributable to shareholders for the same period was HKD 108.84 million, a decrease of 6% from HKD 115.82 million year-on-year[4]. - The food biotechnology segment generated revenue of HKD 7.84 billion, an increase of 11% year-on-year, but the segment profit (excluding share of profits from associates) decreased by 12% to HKD 138 million[8]. - The company maintained a total asset value of HKD 5.08 billion, reflecting a 3% increase from HKD 4.94 billion as of December 31, 2024[4]. - The equity attributable to shareholders rose by 4% to HKD 2.70 billion compared to HKD 2.59 billion at the end of 2024[4]. - The tinplate business produced and sold 240,000 tons of products, representing increases of 9% and 12% respectively, with segment profit rising by 81% to HKD 59.29 million[9]. - The company recorded a valuation gain of HKD 30,000 on investment properties, a significant improvement from a valuation loss of HKD 6.75 million in the previous year[10]. Market Challenges - The company continues to face challenges in the food biotechnology business due to fluctuations in pork prices and increased competition in the market[11]. - The overall market share for live pig distribution in Hong Kong decreased to 48%, down from 49% in the same period last year[8]. Retail Operations - The company is expanding its retail operations in Hong Kong, currently operating 19 retail stores[8].
广南(集团)(01203) - 2025 Q3 - 季度业绩